Gland Pharma Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is HEPARIN SODIUM USP, with a corresponding US DMF Number 23839.
Remarkably, this DMF maintains an Active status since its submission on April 19, 2010, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 20, 2013, and payment made on February 28, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II